

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
24 August 2023 (24.08.2023)



(10) International Publication Number
WO 2023/155004 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) A61K 31/675 (2006.01)
A61K 31/519 (2006.01) C07F 9/6561 (2006.01)

(21) International Application Number:

PCT/CA2023/050195

(22) International Filing Date:

15 February 2023 (15.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/268,021 15 February 2022 (15.02.2022) US

(71) Applicant: **INVERSAGO PHARMA INC.** [CA/CA];
1100 René-Lévesque West, Suite 1110, Montreal, Québec
H3B 4N4 (CA).

(72) Inventors: **GREEN, Jeremy**; 125 Lincoln Woods
Road, Waltham, Massachusetts 02451 (US). **GAL-
LAGHER-DUVAL, Shawn**; 2525 Av. Marie Curie, Mon-
treal, Québec H4S 2E1 (CA). **LEMIRE, Alexandre**; 2525
Av. Marie Curie, Montreal, Québec H4S 2E1 (CA). **ZHOU,
Yuchen**; 63 Av. de Portsmouth, Pointe-Claire, Québec H9R
5T5 (CA). **WANG, Hong**; 207-248 Elgar Street, Verdun,
Québec H3E 1C8 (CA).

(74) Agent: **ROBIC S.E.N.C.R.L / LLP**; 630 Rene-Levesque
Boulevard West, 20th Floor, Montreal, Québec H3B 1S6
(CA).

(81) Designated States (unless otherwise indicated, for every


kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF



(57) Abstract: The present document relates to pyrazolopyrimidine com-
pounds, pharmaceutical compositions comprising the same and their use in
the treatment or prevention of diseases and disorders associated with the
cannabinoid CB₁ receptor. For example, the pyrazolopyrimidine compounds,
or a tautomeric form and/or salt thereof, are of Formula I: Formula I wherein
R¹ to R⁴ are as defined herein.

WO 2023/155004 A1